Last reviewed · How we verify
Libramed
Libramed is a Small molecule drug developed by Azienda Ospedaliera Universitaria Integrata Verona. It is currently in Phase 1 development. Also known as: Policaptil Gel Retard.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Libramed |
|---|---|
| Also known as | Policaptil Gel Retard |
| Sponsor | Azienda Ospedaliera Universitaria Integrata Verona |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ABO-GLYC in Type 2 Diabetes (NA)
- Effects of Intake of a Polysaccharides Mix on Metabolism, Hormones and Satiety in Obese Children. (PHASE1, PHASE2)
- Evaluation of Libramed in Obesity Treatment (NA)
- Policaptil Gel Retard® in Overweight and Mild Obese Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Libramed CI brief — competitive landscape report
- Libramed updates RSS · CI watch RSS
- Azienda Ospedaliera Universitaria Integrata Verona portfolio CI
Frequently asked questions about Libramed
What is Libramed?
Who makes Libramed?
Is Libramed also known as anything else?
What development phase is Libramed in?
Related
- Manufacturer: Azienda Ospedaliera Universitaria Integrata Verona — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Policaptil Gel Retard
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing